DJIA 17,753.99 8.01 0.05%
NASDAQ 5,151.38 22.59 0.44%
S&P 500 2,112.48 3.85 0.18%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

0.00 0.00 (0.00%)

Quote as of


company name or ticker

Recent Quotes

GEVA 0.00 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open 0.00
Previous Close 0.00
Daily Range 0.00 - 0.00
52-Week Range 0.00 - 0.00
Market Cap 0.0000
P/E Ratio 0.00
Dividend (Yield) 0.00 (0.0%)
Volume 0
Average Daily Volume 0
Current FY EPS -7.23

Sector

Healthcare

Industry

Drug Makers

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website: http://www.synageva.com/

News & Commentary

Is it Time for this Biotech to Change Management?

With Aegerion Pharmaceuticals down 500% from its all-time high, the current CEO's tenure is trying investors' patience.

Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk

JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue

Bernstein: Alexion Pharma An Outperform, Worth $267/Share

New Lifetime High Today: Synageva BioPharma (GEVA)

5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary

13.8% Annual Return With Synageva BioPharma

Synageva Reports Closing of Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopholysacchar

Synageva Reports Closing of Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopholysaccharidosis IIIB

Insider Wisdom And The New Medicine

Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog

See More GEVA News...

GEVA's Top Competitors

GEVA 0.00 (0.00%)
Current stock: GEVA
AMGN $178.20 (3.79%)
Current stock: AMGN
GILD $118.44 (0.46%)
Current stock: GILD
BIIB $321.76 (1.50%)
Current stock: BIIB